FABRICATION AND CHARACTERIZATION OF SOLID LIPID NANOPARTICLES OF CEFTRIAXONE SODIUM
Main Article Content
Keywords
Abstract
Solid lipid nanoparticles are typically spherical with an average diameter between 1 and 1000 nm. It is an alternative carrier system to tradition colloidal carriers, such as, emulsions, liposomes, and polymeric micro and nanoparticles. Ceftriaxone sodium is used to treat a wide variety of bacterial infections. This medication belongs to a class of drugs known as cephalosporin antibiotics. It works by stopping the growth of bacteria. Ceftriaxone is a broad spectrum antibiotic used against a number of bacterial infections in spite of its many associated side effects including the appearance of rashes on the skin, diarrhea, elevation in liver enzymes, blood urea nitrogen, eosinophilia, thrombocytosis, and other local reactions. It is widely used in meningitis, endocarditis, pneumonia, gonorrhea, pelvic inflammatory disease and ear, bone, joint, intra-abdominal, skin and urinary tract infections. This antibiotic has been found effective against several infectious and microbial diseases. To overcome the side effects and to increase the bioavailability solid lipid nanoparticles of Ceftriaxone sodium were prepared by using lipids (phosphotidylcholine and triglycerides) with stabilizers (tween 80). The prepared formulations have been evaluated for entrapment efficiency, drug content, in-vitro drug release, particle size analysis, scanning electron spectroscopy, Fourier transform-infrared studies, and stability. A formulation containing solid lipid PC:triasterine stabilized with tween 80 as surfactant showed prolonged drug release, smaller particle size, and narrow particle size distribution, as compared to other formulations with different surfactants and lipids.
Downloads
References
1. AHFS; Drug Information, American society of Health-system Pharmacists, Inc. 7272 Wisconsin Avenue, Bethseda, MD 20814,2004:1869-75. 2. Huh, A.J., Kwon, Y.J., 2011. Nanoantibiotics: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J. Control. Release 156, 128–145. 3. Kalhapure, R.S., Suleman, N., Mocktar, C., Seedat, N., Govender, T., 2015. Nanoengineered drug delivery systems for enhancing antibiotic therapy. J. Pharm. Sci. 104, 872–905. 4. Shiffman, M.L., Keith, F.B., Moore, E.W., 1990. Pathogenesis of ceftriaxone-associated biliary sludge. Gastroenterology 99, 1772–1778. 5. Shrimali, J.D., Patel, H.V., Gumber, M.R., Kute, V.B., Shah, P.R., Vanikar, A.V., Trivedi, H. L., 2013. Ceftriaxone induced immune hemolytic anemia with disseminated intravascular coagulation. Indian J. Crit. Care Med. 17, 394–395. 6. Kumar, S., Bhanjana, G., Sharma, A., Sidhu, M., Dilbaghi, N., 2014. Synthesis, characterization and on field evaluation of pesticide loaded sodium alginate nanoparticles. Carbohydr. Polym. 101, 1061–1067. 7. Kumar, S., Bhanjana, G., Sharma, A., Sidhu, M., Dilbaghi, N., 2015. Herbicide loaded carboxymethyl cellulose nanocapsules as potential carrier in agrinanotechnology. Sci. Adv. Mater. 7, 1143–1148. 8. Kuo, Y.C., Chen, H.H., 2009. Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles. Int. J. Pharm. 365, 206–213. 9. Lim, S.B., Banerjee, A., Onyuksel, H., 2012. Improvement of drug safety by the use of lipid-based nanocarriers. J. Control. Release 163, 34–45. 10. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. Indian J Pharm. Sci 2009;71:349-58. 11. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – A review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77. 12. Luo Y, Chen D, Ren L, Zhao X, Qin J. Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability. J Control Release 2006;114:53-9. 13. Huang G, Zhang N, Bi X, Dou M. Solid lipid nanoparticles of temozolomide: Potential reduction of cardial and nephric toxicity. Int J Pharm 2008;355:314-20. 14. Abdelbary G, Fahmy RH. Diazepam – loaded solid lipid nanoparticles: Design and characterization. AAPS PharmSciTech 2009;10:211-9. 15. Heinzelmann ME, Wiesendanger R. Scanning tunneling microscopy II surface science. Newyork: Springer verlogg; 1992. P. 99-149. 16. Bhalekar MR, Pokharkar V, Madgulkar A, Patil N, Patil N. Preparation and evaluation of miconazole nitrate-loaded dolid lipid nanoparticles for topical delivery. AAPSPharmSciTech 2009;10:289-96. 17. Suresh G, Manjunath K, Venkateswarlu V, SatyanarayanaV. Preparation, characterization, in-vitro and in-vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech 2007 Mar 23;8:24. 18. Zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and mechanism. Eur J Pharm Biopharm 1998;45:149-55. 19. Jawahar N, Eaggapanath T, Nagaswamy V, Samantha JS. Preparation and characterization of PLGA – Nanoparticles containing a hypertensive agent. Int J Pharm Tech Res 2009;2:390-3.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.